For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Cohort 1: SDX/d-MPH in 4-5 Year Olds | 13.1 mg/2.6 mg SDX/d-MPH, 26.1 mg/5.2 mg SDX/d-MPH, 39.2 mg/7.8 mg SDX/d-MPH Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH): Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH) | 0 | None | 0 | 65 | 29 | 65 | View |
| Cohort 1: Placebo in 4-5 Year Olds | matching placebo dose levels placebo: matching placebo | 0 | None | 0 | 69 | 15 | 69 | View |
| Cohort 2: SDX/d-MPH in 6-12 Year Olds | 13.1 mg/2.6 mg SDX/d-MPH, 26.1 mg/5.2 mg SDX/d-MPH, 39.2 mg/7.8 mg SDX/d-MPH, 52.3 mg/10.4 mg SDX/d-MPH Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH): Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH) | 0 | None | 0 | 54 | 28 | 54 | View |
| Cohort 2: Placebo in 6-12 Year Olds | matching placebo dose levels placebo: matching placebo | 0 | None | 0 | 55 | 11 | 55 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Insomnia | NON_SYSTEMATIC_ASSESSMENT | Psychiatric disorders | MedDRA Version 25.1 | View |
| Irritability | NON_SYSTEMATIC_ASSESSMENT | Psychiatric disorders | MedDRA Version 25.1 | View |
| Gastrointestinal disorders | NON_SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | MedDRA Version 25.1 | View |
| Decreased appetite | NON_SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | MedDRA Version 25.1 | View |
| Infections and Infestations | NON_SYSTEMATIC_ASSESSMENT | Infections and infestations | MedDRA Version 25.1 | View |
| Investigations | NON_SYSTEMATIC_ASSESSMENT | Investigations | MedDRA Version 25.1 | View |
| Nervous system disorders | NON_SYSTEMATIC_ASSESSMENT | Nervous system disorders | MedDRA Version 25.1 | View |